Each lot of this antibody is quality control tested by Western blotting. Western blotting, suggested working dilution(s): Use 10 μl per 5 ml antibody dilution buffer for each mini-gel. It is recommended that the reagent be titrated for optimal performance for each application.
MCF-7 cell extract (Lane 1) or NIH3T3 cell extract (Lane 2) was resolved by electrophoresis, transferred to nitrocellulose and probed with rabbit polyclonal antibody against CBP. Proteins were visualized using a donkey anti-rabbit secondary conjugated to HRP and a chemiluminescence detection system.
Description:
CBP (also known as CREB-binding protein and CBP/p300) is a widely expressed nuclear protein that contains a bromodomain, a ZZ-type zinc domain, and TAZ-type zinc fingers. This 265 kD acetyltransferase enzyme, acetylates histones and non-histone proteins like NCOA3 coactivator and mediates c-AMP gene regulating by binding to phosphorylated CREB. CBP and phosphorylated CREB activates transcription of c-AMP responsive genes; defects in CBP result in Rubinstein-Taybi syndrome (mental retardation, craniofacial defects, heart defects). CBP is activated by TCR signaling and is involved in TNF-α gene expression and plays a central role in regulating gene responses to hypoxia. This protein is acetylated at multiple sites. CBP has been shown to interact with NCOA6, androgen receptor, STAT6, SRC1, Csk, FKHR, and c-jun and to form a complex with NCOA2, NCOA3, IKKA, IKKB, and IKBKG. In addition, CBP probably forms a complex with HIF1A and EP300. The Poly6064 antibody has been shown to be useful for Western blotting of the human and mouse CBP protein.
Acetyltransferase enzyme, acetylates histones and non-histone proteins like NCOA3 coactivator. Mediates c-AMP gene regulating by binding to phosphorylated CREB. CBP and phosphorylated CREB activates transcription of c-AMP responsive genes; defects result
Regulation:
Activated by TCR signaling and involved in TNF-α gene expression, central role in regulating gene responses to hypoxia
Modification:
Acetylation at multiple sites
Interaction:
SMAD1, SMAD2, SMAD3, PCAF, NCOA6, androgen receptor, STAT6, SRC1, Csk, FKHR, and c-jun, forms a complex with NCOA2, NCOA3, IKKA, IKKB, and IKBKG. Probably forms a complex with HIF1A and EP300
Antigen References:
1. Arany, Z., et al., 1996. PNAS 93:12969. 2. MuRata, T., et al., 2001. Hum. Mol. Genet. 10:1071. 3. Falvo, J., et al., 2000. PNAS 97:3925.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering/). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
